Directly from ESC 2024 - OCEANIC-AF: Asundexian Patients Have Nearly 4x Stroke, Embolism Risk vs Apixaban Patients
The OCEANIC-AF trial has missed its primary endpoint, with use of asundexian nearly quadrupling the risk of stroke or systemic embolism compared with apixaban among high-risk patients with atrial fibrillation.
Presented at the European Society of Cardiology (ESC) Congress 2024, results of the study demonstrate the factor XIa inhibitor failed to achieve its primary endpoint but was associated with a reduction in major bleeding events relative to apixaban.
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
Source: MDMag
